-
An FDA reviewer recommended approval of 2.5 mg twice-daily Xarelto rivaroxaban from Johnson & Johnson (NYSE:JNJ) to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS), non-ST-…
Published on 5/21/2012
-
Contrary to media reports saying otherwise, Cancer Genetics Inc. (Rutherford, N.J.) has not postponed its planned IPO, according to a source familiar with the deal. The source said the market conditions are "not ideal" …
Published on 5/18/2012
-
Exelixis Inc. (NASDAQ:EXEL) released an abstract showing no difference between cabozantinib and placebo in overall survival at an interim analysis in the Phase III EXAM trial in 330 patients with advanced medullary …
Published on 5/17/2012
-
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) raised $60.5 million through the sale of 11 million shares at $5.50 in a follow-on underwritten by Jefferies; Piper Jaffray; and BMO Capital Markets. The company proposed the …
Published on 5/16/2012
-
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will acquire the 80.02% of proteomics company Cellzome AG (Heidelberg, Germany) it does not already own for L61 million ($98 million) in cash. GSK said Cellzome's proteomic mass …
Published on 5/15/2012
-
Intercell AG (VSE:ICLL; OTCQX:INRLY) raised EUR 35.2 million ($45.3 million) in a debt and equity financing. The financing comprised EUR 20 million ($25.8 million) in a secured loan from BB Biotech; and EUR 15.2 million…
Published on 5/14/2012
-
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped $2.70 (74%) to $6.36 on Friday after an FDA advisory committee voted 18-4, with one abstention, that the benefit-risk profile for Arena's lorcaserin supports approval to …
Published on 5/11/2012
-
FDA's Antiviral Drugs Advisory Committee concluded the benefit-risk profile for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) supports the drug's use as pre-exposure prophylaxis (PrEP) to …
Published on 5/10/2012
-
FDA's Arthritis Advisory Committee voted 8-2 in favor of recommending approval of tofacitinib from Pfizer Inc. (NYSE:PFE) to treat moderately to severely active rheumatoid arthritis (RA) in patients who have had …
Published on 5/9/2012
-
Actelion Ltd. (SIX:ATLN) said it plans to reduce R&D and overhead spending by refocusing R&D activities on specialty areas and out-licensing its primary care programs. Actelion did not provide details on specific cuts.…
Published on 5/8/2012
-
Roche (SIX:ROG; OTCQX:RHHBY) lost CHF5 billion ($5.4 billion) in market cap on Monday after discontinuing development of cardiovascular compound dalcetrapib. The pharma, which now has a market cap of CHF138.6 billion ($…
Published on 5/7/2012
-
FDA reviewers said Arcalyst rilonacept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) had a "small" treatment effect to prevent gout flares in adults initiating uric acid-lowering therapy and that the drug appears to…
Published on 5/4/2012
-
Royalty Pharma (New York, N.Y.) paid former shareholders of Fumapharm AG $761 million in cash to acquire a portion of earn-out rights related to multiple sclerosis (MS) product BG-12 and psoriasis drug Fumaderm. The …
Published on 5/3/2012
-
Nature published a revised version of the first of two studies on H5N1 transmissibility in mammals on Wednesday after over four months of debate among academics and government officials about the potential for misuse of…
Published on 5/2/2012
-
FDA approved an NDA late Tuesday from Pfizer Inc. (NYSE:PFE) for Elelyso taliglucerase alfa to treat Type I Gaucher's disease. The news sent shares of partner Protalix Biotherapeutics Inc. (NYSE-A:PLX; Tel Aviv:PLX) up…
Published on 5/1/2012
-
Actelion Ltd. (SIX:ATLN) gained CHF4.60 (14%) to CHF38.40 on Monday after macitentan met the primary endpoint of reducing a composite of time to first morbidity or mortality event vs. placebo in the Phase III SERAPHIN …
Published on 4/30/2012
-
Boehringer Ingelheim GmbH (Ingelheim, Germany) told BioCentury it broke off pricing negotiations with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) for diabetes drug Trajenta linagliptin. …
Published on 4/27/2012
-
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will acquire cancer-focused specialty pharma EUSA Pharma Inc. (Langhorne, Pa.) for $650 million in cash, plus a potential $50 million payment tied to 2013 U.S. sales of EUSA's …
Published on 4/26/2012
-
Amgen Inc. (NASDAQ:AMGN) said it will acquire 95.6% of Mustafa Nevzat Pharmaceuticals A.S. (Istanbul, Turkey) in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat, which recorded about $200 …
Published on 4/25/2012
-
Amgen Inc. (NASDAQ:AMGN) said founding CEO George Rathmann died Sunday. Rathmann, 84, had suffered from kidney failure. He was Amgen's founding CEO from 1980-88 and chairman until 1990. He later co-founded and was …
Published on 4/24/2012
-
AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire Ardea Biosciences Inc. (NASDAQ:RDEA) for $32 per share, or about $1.3 billion. The price is a 54% premium to Ardea's close of $20.84 on Friday, before the deal was …
Published on 4/23/2012
-
EMA's CHMP issued several positive opinions on Friday, including one in favor of Forxiga dapagliflozin from Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat Type II diabetes. …
Published on 4/20/2012
-
Human Genome Sciences Inc. (NASDAQ:HGSI) rejected an unsolicited takeover offer from partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for $13 per share, or about $2.6 billion in cash. The price is an 81% premium to Human…
Published on 4/19/2012
-
The U.S. House Energy and Commerce Committee released a discussion draft of PDUFA reauthorization legislation on Wednesday. The Senate Health, Education, Labor and Pensions Committee also posted draft versions of PDUFA …
Published on 4/18/2012
-
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Five Prime Therapeutics Inc. (South San Francisco, Calif.) partnered to identify targets and drug candidates relevant to refractory asthma and chronic obstructive pulmonary …
Published on 4/17/2012